Galecto Gets Orphan Drug Designation from EMA for Pulmonary Fibrosis Drug

The European Medicines Agency (EMA) has granted Galecto’s investigational drug GB0139 an Orphan Drug designation for the treatment of idiopathic pulmonary fibrosis.

The EMA granted the designation based on results from a study in which GB0139 showed a significant reduction of the chitinase-like protein YKL-40, a common biomarker in diseases with fibrosis, inflammation and tissue remodeling.

GB0139 is currently in phase 2 testing for idiopathic pulmonary fibrosis in the U.S., the European Union and Canada.